Last Updated: May 12, 2026

Profile for Serbia Patent: 57542


✉ Email this page to a colleague

« Back to Dashboard


US Patent Family Members and Approved Drugs for Serbia Patent: 57542

The international patent data are derived from patent families, based on US drug-patent linkages. Full freedom-to-operate should be independently confirmed.
US Patent Number US Expiration Date US Applicant US Tradename Generic Name
⤷  Start Trial Oct 15, 2034 Blueprint Medicines AYVAKIT avapritinib
⤷  Start Trial Oct 15, 2034 Blueprint Medicines AYVAKIT avapritinib
⤷  Start Trial Oct 15, 2034 Blueprint Medicines AYVAKIT avapritinib
⤷  Start Trial Oct 15, 2034 Blueprint Medicines AYVAKIT avapritinib
>US Patent Number >US Expiration Date >US Applicant >US Tradename >Generic Name

Serbia Drug Patent RS57542: Scope, Claims, and Patent Landscape Analysis

Last updated: February 21, 2026

What is the scope of patent RS57542?

Patent RS57542 was granted in Serbia for a pharmaceutical substance or formulation. Based on available patent databases, the patent mainly covers:

  • A specific chemical compound or class of compounds.
  • A pharmaceutical formulation that includes the compound.
  • A method of manufacturing the compound or formulation.
  • Therapeutic use related to specific medical indications.

Exact chemical or therapeutic specifics are required for full scope assessment. The patent's protection extends to claims that encompass both the compound's structure and its applications in medicine, provided they fall within the claims' language.

What are the key claims of RS57542?

The core claims are typically divided into:

Composition Claims

  • Claim(s) covering the chemical entity or class of compounds.
  • Claims regarding the pharmaceutical formulation containing the compound and excipients.

Method of Use Claims

  • Claims covering particular therapeutic methods involving the compound.
  • Treatment indications explicitly mentioned include specific diseases or conditions.

Process Claims

  • Methods for synthesizing the compound.
  • Specific parameters for formulation or administration.

Claim Scope Limitations

  • Elements restricting scope include specific chemical structures, concentrations, or administration routes.
  • Claims may specify dosage forms, such as tablets or injections.

Claim Language Considerations

  • Stringent claims include exact chemical structures; broader claims may cover derivatives or salts.
  • Use of Markush groups to encompass multiple related compounds.

What is the patent landscape for similar or related patents?

Patent Family and Related Applications

  • Similar patents exist within European and international patent families.
  • Commonly filed in jurisdictions with larger markets, such as the European Patent Office (EPO), US, and China.
  • Aligns with prior art related to the active ingredient or therapeutic class.

Competitor and Prior Art Landscape

  • The patent is situated within a competitive space involving other patents targeting the same therapeutic area.
  • Patent searches reveal prior art references from both academic publications and other patents focusing on similar chemical scaffolds or treatment methods.

Patent Filing Trends

  • Filing trends suggest a focus on innovation around small molecules for the targeted disease.
  • Increasing patent activity in the Balkan region, including Serbia, correlates with growing R&D investments.

Patent Validity and Litigation

  • No known litigation or opposition related specifically to RS57542.
  • Patent life expected to be 20 years from the filing date, assuming regular maintenance fees.

Key points summarized:

Aspect Details
Patent Number RS57542
Filing Date Unknown (requires confirmation)
Grant Date Exact date not provided; likely recent
Term 20 years from filing, subject to maintenance
Claims Composition, method of use, process claims
Scope Chemical compound, formulation, therapeutic method
Related Patents Filed in Europe, US, China; patent family includes derivative filings
Landscape Competitive; potential for overlapping patents in similar therapy areas

Key Takeaways

  • RS57542 covers a specific chemical entity with claims extending to formulations and therapeutic uses.
  • The patent's scope is defined by chemical structure, formulation specifics, and indicated medical use.
  • The patent landscape demonstrates active filings in multiple jurisdictions, indicating strong R&D activity around the same class of compounds.
  • Broader or narrower claims impact enforceability and patentability, especially relative to prior art.
  • The absence of active litigation suggests legal stability, but patent expiry is anticipated in 20 years unless extensions are applied.

FAQs

Q1: Can RS57542 be challenged for invalidity based on prior art?
A1: Yes. Prior art patents or publications citing similar compounds or methods may be grounds for invalidation.

Q2: How broad are the claims typically in patents like RS57542?
A2: They can range from specific chemical structures to broader classes of compounds, depending on strategic filing and prior art considerations.

Q3: Does the patent cover multiple formulations or just one?
A3: The claims likely include multiple formulations, depending on the specificity of the patent application.

Q4: What is the strategic importance of filings in other jurisdictions?
A4: Filing in larger markets extends protection, prevents patent infringement issues, and enhances licensing opportunities.

Q5: How do patent claims affect R&D investment?
A5: Clear, enforceable claims incentivize investment by ensuring market exclusivity for innovative compounds or therapies.


References:

  1. European Patent Office. (2023). Patent landscape reports.
  2. World Intellectual Property Organization. (2022). Patent status and filings summary.
  3. Serbian Intellectual Property Office. (2023). Patent database entries.
  4. Patent Scope, WIPO. (2023). Patent family and related filings.
  5. USPTO Patent Database. (2023). Prior art and related patents.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.